Robert L. De Jager, M.D., F.A.C.P. Joins Conforma Therapeutics Corporation As Vice President, Clinical Research & Development And Chief Medical Officer
10/19/2005 5:11:46 PM
Conforma Therapeutics Corporation today announced the appointment of Robert L. De Jager, M.D., F.A.C.P to the newly created position of vice president, clinical research and development and chief medical officer. In this position, Dr. De Jager will oversee the clinical evaluation of CNF1010, Conforma's geldanamycin-derived HSP90 inhibitor currently in Phase I clinical trials in cancer, and CNF2024, a synthetic oral HSP90 inhibitor recently selected as a clinical candidate and expected to enter clinical trials in cancer in 2005.
comments powered by